Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Risk factors

Topic: Risk, prevention and care in population studies

Plain-language summary

Rationale & Objective Among older patients with kidney failure, those who are minoritized or residing in rural areas experience a disproportionate burden of Alzheimer's disease and related dementias (ADRD). Neighborhood disadvantage drives health disparities, but few studies have directly examined its association with ADRD and whether this association varies by race/ethnicity and by urbanicity. Study Design Cohort study. Setting & Participants United States Renal Data System data; older patients (age ≥55 years) initiating dialysis in 2003-2021. Exposures Residential neighborhood disadvantage was measured using a ZIP-code level index across nine domains (built environment, criminal justice, education, employment, housing, poverty, social fragmentation, transportation, and wealth). Outcome ADRD using diagnosis codes. Analytical Approach We used cause-specific hazards models to quantify the adjusted hazard ratios (aHR) of ADRD diagnoses. We then used interaction terms to quantify whether these associations differed by race/ethnicity and urbanicity. Results After adjustments, older patients in high-disadvantage neighborhoods had a higher risk of ADRD diagnoses (dementia: aHR=1.09, 95%CI:1.08-1.10; AD: aHR=1.25, 95%CI:1.22-1.27) compared to older patients in low-disadvantage neighborhoods; these associations differed by race/ethnicity (dementia: P interaction =0.03; AD: P interaction =0.002) and by urbanicity (P interactions <0.001 for both). Specifically, older Black patients in high-disadvantage neighborhoods had a higher risk of ADRD (dementia: aHR=1.19, 95%CI:1.17-1.21; AD: aHR=1.31, 95%CI:1.28-1.35) compared to older Black patients in low-disadvantage neighborhoods. Within suburban, rural, and small-town areas, older patients residing in high-disadvantage neighborhoods had a higher risk of ADRD compared with those in low-disadvantage neighborhoods. Limitations ZIP codes as a proxy for neighborhoods. Conclusions Older patients with kidney failure residing in high-disadvantage neighborhoods, particularly Black patients and those in suburban, rural, or small-town areas, had a higher risk of ADRD compared with those in low-disadvantage neighborhoods. Multifaceted interventions ( e.g., cognitive screening, collaborative care) are needed to mitigate structural barriers associated with neighborhood disadvantage and preserve cognitive function in this population.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study. This cohort study found that older patients with kidney failure in high-disadvantage neighborhoods had a higher risk of Alzheimer's disease and related dementias diagnoses, with the association differing by race and ethnicity. Reported effect size: aHR=1.09; aHR=1.25; aHR=1.19.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Li, Y., Menon, G., Long, J. J., Kim, B., Bae, S., Orandi, B. J., et al. (2026). Neighborhood Disadvantage and Dementia Risk Among Older Patients With Kidney Failure: Differences by Race/Ethnicity and Urbanicity. Kidney Medicine. https://doi.org/10.1016/j.xkme.2026.101479

Vancouver

Li Y, Menon G, Long JJ, Kim B, Bae S, Orandi BJ, et al. Neighborhood Disadvantage and Dementia Risk Among Older Patients With Kidney Failure: Differences by Race/Ethnicity and Urbanicity. Kidney Medicine. 2026. doi:10.1016/j.xkme.2026.101479.

BibTeX

@article{li2026-755a93c8,
  author  = {Li, Yiting and Menon, Gayathri and Long, Jane J. and Kim, Byoungjun and Bae, Sunjae and Orandi, Babak John and DeMarco, Mario P. and Wu, Wenbo and others},
  title   = {{Neighborhood Disadvantage and Dementia Risk Among Older Patients With Kidney Failure: Differences by Race/Ethnicity and Urbanicity}},
  journal = {Kidney Medicine},
  year    = {2026},
  doi     = {10.1016/j.xkme.2026.101479},
  url     = {https://doi.org/10.1016/j.xkme.2026.101479}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This cohort study found that older patients with kidney failure in high-disadvantage neighborhoods had a higher risk of Alzheimer's disease and related dementias diagnoses, with the association differing by race and ethnicity. The findings concern neighborhood disadvantage as a risk factor and do not test any treatment, cure, or prevention.

Study details

How this study scored 45/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 3 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. Total 45 of 100.45 of 100 points earned55 not earned

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Kidney Medicine)
Journal's citation record 0 / 4 Kidney Medicine: journal h-index 46 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Mara McAdams‐DeMarco: h-index 64 (OpenAlex, whole career)
Institution's track record 2 / 3 Johns Hopkins University: institution h-index 2,306 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Total 45 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

Related studies in Risk factors from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk factors

See all studies in Risk factors →